Provided by Tiger Fintech (Singapore) Pte. Ltd.

Merck

94.65
+0.65000.69%
Post-market: 94.900.2500+0.26%19:54 EST
Volume:24.10M
Turnover:2.30B
Market Cap:239.09B
PE:14.04
High:97.37
Open:94.26
Low:93.85
Close:94.00
Loading ...

Is Summit Therapeutics a Millionaire Maker?

Motley Fool
·
09 Feb

2 Stocks That Could Soar Again in 2025

Motley Fool
·
08 Feb

Merck & Company Executives Make Bold Moves with Stock Transactions

TIPRANKS
·
08 Feb

BUZZ-US stocks weekly: Fumble!

Reuters
·
08 Feb

Health Rounds: Vaccine shows promise against advanced kidney cancer

Reuters
·
07 Feb

Merck & Co. Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
07 Feb

Earnings Update: Merck & Co., Inc. (NYSE:MRK) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Simply Wall St.
·
07 Feb

Trump faces pressure from US industry over China tariff on medicines

Reuters
·
07 Feb

Merck Initiates Phase 3 Trial of Zilovertamab Vedotin Antibody-Drug Conjugate to Treat Lymphoma

MT Newswires Live
·
06 Feb

Merck Announces Phase 3 Waveline-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

THOMSON REUTERS
·
06 Feb

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Fortune
·
06 Feb

Analysts Defend Merck Amid Investor Concerns Over Weak Guidance

Benzinga
·
06 Feb

News Highlights: Top Company News of the Day - Wednesday at 1 PM ET

Dow Jones
·
06 Feb

Merck Is Maintained at Market Perform by BMO Capital

Dow Jones
·
05 Feb

Dow's 140-Point Fall Led By Losses For Shares Of UnitedHealth, Merck

Dow Jones
·
05 Feb

UBS Adjusts Price Target on Merck to $105 From $120, Maintains Buy Rating

MT Newswires Live
·
05 Feb